Overview

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Status:
Not yet recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

InnoPharmax Inc.

Treatments:

Capecitabine